A British pharmaceutical company is getting closer to a decision on whether the U.S government will approve the first prescription drug derived from the marijuana plant, but parents who for years have used cannabis to treat severe forms of epilepsy in their children are feeling more cautious than celebratory.
The U.S. Food and Drug Administration is expected to decide by the end of the month whether to approve GW Pharmaceuticals’ Epidiolex. It’s a purified form of cannabidiol — a component of cannabis that doesn’t get users high — to treat Dravet and Lennox-Gastaut syndromes in kids. Both forms of epilepsy are rare.
Cannabidiol’s effect on a variety of health conditions is frequently touted, but there is still little evidence to back up advocates’ personal experiences. The U.S. Drug Enforcement Administration has long categorized cannabis as a Schedule I drug, a category with “no currently accepted medical use and a high potential for abuse.” That strictly limits research on potential medical uses for cannabis or the chemicals in it, including cannabidiol, or CBD.
But for years, parents desperate to find anything to help their children have turned to the marijuana-based products made legal by a growing number of states. [Read more at Colorado Public Radio]
Your email address will not be published. Required fields are marked *
Name *
Email *
Website
Save my name, email, and website in this browser for the next time I comment.
Comment *
Notify me of follow-up comments by email.
Notify me of new posts by email.
Δ
Confidential documents obtained by THE CITY reveal how Chicago Atlantic Group became one of the biggest beneficiaries of the state’s legalization program. Last June, Gov. Kathy Hochul announced that a…
April 20 is a day recognized globally for celebrating cannabis culture, but it’s also like the cannabis industry’s Black Friday. Dispensaries offer deals designed to inspire people to flood their stores…
Japan’s cannabis market expanded sixfold over four years to Â¥24 billion ($154 million) in 2023, a trend that is expected to accelerate with the amendment in December of cannabis laws,…
Los Angeles-based Ispire Technologies (NASDAQ: ISPR) is a three-year-old company built on the foundation (and reputation) of a global enterprise with many years of experience as an ODM (original design…